Followers | 53 |
Posts | 7442 |
Boards Moderated | 0 |
Alias Born | 08/24/2010 |
Thursday, April 02, 2020 8:48:26 AM
Pathways specific to COVID-19
Coronavirus Treatment Acceleration Program
What it is: A “special emergency program” intended to accelerate the review of therapies intended to treat, cure or prevent COVID-19. The review program “uses every available method to move new treatments to patients as quickly as possible.” The pathway combines many elements from other review programs and pathways listed below, such as rolling review, accelerated timelines, hands-on support from FDA review staff and more.
The pathway is intended to begin early in clinical development, with the FDA providing “ultra-rapid, interactive input on most development plans,” review of clinical protocols within 24 hours of submission, review of single patient expanded access requests “generally within 3 hours” and working collaboratively to conduct quality assessments and transfer manufacturing “to avoid supply disruption.”
What it’s generally used for: The acceleration of medical therapies intended to treat, cure or prevent COVID-19.
Limitations: As with other review acceleration methods, the FDA’s ultra-rapid review will only be as useful as the ability of a company to move quickly to establish a manufacturing site, generate and analyze data, and make submissions. The ultra-rapid reviews may also miss some critical safety or efficacy issues that might have been discovered through more extensive analysis.
How it could be used in the context of COVID-19: Expect all COVID-19 products to receive an all-hands review by the FDA, with some product reviews taking place in days instead of months. The FDA says it plans to “continue to enhance and expand CTAP,” so further changes are expected soon.
Further reading: Coronavirus Treatment Acceleration Program
Also known as: CTAP
Regulatory/Legal authority: N/A. More akin to a pilot program, and not established under regulation or statute.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM